Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 7531-7540 Newer>

The Motley Fool June 9, 2011	CLARCOR Earnings Preview Investors hope CLARCOR will top analyst estimates once again after beating predictions by 1 cent in the previous quarter.
The Motley Fool June 9, 2011 Brian Orelli	It's a Numbers Game With Vertex In the longer term, the number of patients Vertex can address with its cystic fibrosis drugs will play a major role in its valuation.
The Motley Fool June 9, 2011 Brian Orelli	Get Out of Here! $0.5 Million to License a Drug? Somaxon licenses rights to Silenor in Canada, South America, and Africa to Paladin.
The Motley Fool June 9, 2011 Brian Orelli	XOMA Breaks Bad News to Investors XOMA 052 continues to be a disaster in diabetes.
The Motley Fool June 9, 2011 Brian D. Pacampara	Vertex Pharmaceuticals Shares Plunged: What You Need to Know Shares of drug developer Vertex Pharmaceuticals sank as much as 13% after reporting initial data on their combination cystic fibrosis treatment.
Pharmaceutical Executive June 1, 2011	2011 Dealmakers Outlook With Yankee stadium as the backdrop, Pharm Exec convened on March 29 its annual panel of eight business development experts to crack the bat on best practice in licensing for the year ahead.
Pharmaceutical Executive June 1, 2011	Emerging Pharma Leaders 2011 Meet 2011's Emerging Pharma Leaders. Can these 30 trendsetters build competitive scale from scarcity?
Pharmaceutical Executive June 1, 2011	Are You Ready for the New China? The ability to act as a good corporate citizen and assert a useful role in national industrial policy on health is going to be essential to success in the new China.
Pharmaceutical Executive June 1, 2011	Filling in the Bigger Picture Part II of The Avoca Group's 2011 CRO survey on clinical development outsourcing relationships.
Pharmaceutical Executive June 1, 2011 Jill Wechsler	Educating Physicians A communications program is the main component of a Risk Evaluation and Mitigation Strategy to promote safe use of extended-release or long-acting opioids, which have been the subject of FDA/industry negotiations for several years.
<Older 7531-7540 Newer> Return to current articles.